Drug Profile
COPD therapeutic - Medestea
Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Medestea
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Chronic-obstructive-pulmonary-disease in Italy
- 01 Dec 2015 Clinical trials in Chronic obstructive pulmonary disease in Italy (unspecified route)